Cargando…

Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease

Biomarkers useful for diagnosis and evaluation of treatment for patients with Fabry disease are urgently needed. Recently, plasma globotriaosylsphingosine (lyso-Gb3) and lyso-Gb3-related analogues have attracted attention as promising biomarkers of Fabry disease. However, the plasma concentrations o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sueoka, Hideaki, Ichihara, Junji, Tsukimura, Takahiro, Togawa, Tadayasu, Sakuraba, Hitoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428877/ https://www.ncbi.nlm.nih.gov/pubmed/25965380 http://dx.doi.org/10.1371/journal.pone.0127048

Ejemplares similares

Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease
por: Sueoka, Hideaki, et al.
Publicado: (2015)

A Rapid and Simple UHPLC-MS/MS Method for Quantification of Plasma Globotriaosylsphingosine (lyso-Gb3)
por: Perrone, Alessandro, et al.
Publicado: (2021)

Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease
por: Shiga, Tomoko, et al.
Publicado: (2021)

Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
por: Tsukimura, Takahiro, et al.
Publicado: (2021)

Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy
por: Tsukimura, Takahiro, et al.
Publicado: (2020)

Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy
por: Kubota, Takao, et al.
Publicado: (2022)

Cell Transplantation Combined with Recombinant Collagen Peptides for the Treatment of Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2020)

Genetically Modified Cell Transplantation Through Macroencapsulated Spheroids with Scaffolds to Treat Fabry Disease
por: Kami, Daisuke, et al.
Publicado: (2021)

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease
por: Tsukimura, Takahiro, et al.
Publicado: (2014)

Fabry disease in a Japanese population-molecular and biochemical characteristics
por: Sakuraba, Hitoshi, et al.
Publicado: (2018)

Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease
por: Kodama, Takashi, et al.
Publicado: (2011)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease
por: Sakuraba, Hitoshi, et al.
Publicado: (2015)

Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease
por: Nowak, Albina, et al.
Publicado: (2022)

Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease
por: Nikolaenko, Valeria, et al.
Publicado: (2023)

Surface plasmon resonance analysis of complex formation of therapeutic recombinant lysosomal enzymes with domain 9 of human cation-independent mannose 6-phosphate receptor
por: Kanzaki, Minori, et al.
Publicado: (2020)

Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Erratum to: Screening of Fabry disease in patients with chronic kidney disease in Japan
por: Nagata, Akiko, et al.
Publicado: (2021)

Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review
por: Fujisawa, Hironobu, et al.
Publicado: (2019)

Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease
por: Yazd, Hoda Safari, et al.
Publicado: (2021)

Correction: Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2020)

Stoichiometric Quantification of Akt Phosphorylation Using LC-MS/MS
por: Atrih, Abdelmadjid, et al.
Publicado: (2009)

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy
por: Nakano, Sachie, et al.
Publicado: (2015)

The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain
por: Choi, L., et al.
Publicado: (2015)

Lyso-Gb3 Increases αvβ3 Integrin Gene Expression in Cultured Human Podocytes in Fabry Nephropathy
por: Trimarchi, Hernán, et al.
Publicado: (2020)

Pipelines and Systems for Threshold-Avoiding Quantification of LC–MS/MS Data
por: Sánchez Brotons, Alejandro, et al.
Publicado: (2021)

Estimation of measurement uncertainty for the quantification of protein by ID-LC–MS/MS
por: Beasley-Green, Ashley, et al.
Publicado: (2023)

Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018)

Elevated LysoGb3 Concentration in the Neuronopathic Forms of Mucopolysaccharidoses
por: Baydakova, Galina, et al.
Publicado: (2020)

Quantification of cGMP in human plasma by isotope dilution LC-MS/MS
por: Martens-Lobenhoffer, Jens, et al.
Publicado: (2009)

LC-MS/MS Quantification of Tramadol and Gabapentin Utilizing Solid Phase Extraction
por: Nagaraju, Pappula, et al.
Publicado: (2018)

Fast and Simple LC-MS/MS Method for Rifampicin Quantification in Human Plasma
por: Temova Rakuša, Žane, et al.
Publicado: (2019)

Modern Approaches in the Identification and Quantification of Immunogenic Peptides in Cereals by LC-MS/MS
por: Alves, Thais O., et al.
Publicado: (2019)

LC-MS/MS for Ultra-Sensitive Quantification of Multiple Estrogens in the Blood and Brain
por: Jalabert, Cecilia, et al.
Publicado: (2021)

Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2019)

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018)

Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis
por: Maruyama, Hiroki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6qk766g9ml1co1m2djpq9dn5go